A 2026 review in Liver International finds that beta-blockers-especially carvedilol-can help prevent a first decompensation in patients with advanced chronic liver disease (ACLD) who have clinically significant portal hypertension (PH). Authored by Süffert LC et al., the paper synthesizes clinical-trial evidence showing that reducing portal pressure remains central to preventing life‑threatening complications such as ascites, variceal bleeding and hepatic encephalopathy. (Liver Int. 2026; DOI:10.1111/liv.70568.)
ACLD, which often includes cirrhosis, affects roughly 1.3% of the global population and progresses from an often silent compensated phase to decompensation when complications emerge and mortality rises. PH-elevated pressure in the liver’s blood vessels-is the key driver of these complications, so therapies that lower portal pressure are a primary preventive strategy. Beta-blockers lower portal pressure by reducing cardiac output and altering intrahepatic blood flow; trial data summarized in the review indicate they can reduce the risk of a first decompensation in patients with clinically significant PH, most notably by decreasing ascites incidence. Evidence of benefit in patients without clinically significant PH is lacking, so use is generally limited to those with defined portal hypertension.
Among non-selective beta-blockers, carvedilol shows stronger haemodynamic effects than propranolol, producing greater reductions in the hepatic venous pressure gradient (HVPG)—the measured pressure difference used to quantify portal hypertension. Studies in the review suggest carvedilol may better delay first decompensation and may be preferable in later stages, although the overall effectiveness of beta-blockers lessens once decompensation has already occurred.
Safety and benefit vary by disease stage. In compensated ACLD, beta-blockers are usually well tolerated, though not all patients respond and predictors of response remain unclear. In decompensated disease, clinicians must consider a described “therapeutic window”: falling cardiovascular reserve, low blood pressure, renal impairment or refractory ascites can shift the balance toward harm in some patients.
Beta-blockers are one element of multidisciplinary care. Endoscopic variceal ligation (EVL) is an option for those intolerant of medication and is routinely used after bleeding; one trial reviewed found that combining carvedilol with EVL may lower bleeding and mortality in higher‑risk patients, but meta-analyses yield inconsistent results. The review also notes ongoing investigation of other approaches-statins, anticoagulants and metabolic-targeted therapies-which have shown hemodynamic or biological effects but not yet consistent improvements in clinical outcomes.
Overall, the authors advocate a stage-specific, multidisciplinary strategy that integrates beta-blockers for patients with clinically significant PH to help delay first decompensation, while addressing underlying causes such as alcohol use, viral hepatitis and metabolic disease and maintaining preventive care (vaccination, nutrition and surveillance imaging).
Original Source: https://www.emjreviews.com/hepatology/news/rethinking-advanced-liver-disease-treatment-strategies/
Category:
Tags:
Publish Date: 2026-03-22 15:33:00
